Related content

Low-Molecular-Weight Heparin: The Optimal Duration of Prophylaxis Against Postoperative Venous Thromboembolism After Total Hip or Knee Replacement

By Heit J.A.  

Thrombosis Research, Vol. 101, Iss. 1, 2001-01 ,pp. : 163-173

Elsevier

Access to resources Recommend Favorite

Low-molecular-weight heparin vs. a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

By Lee A.Y.Y.   Levine M.N.   Baker R.I.   for the Randomized Comparison of Low-Molecular-Weight Heparin vs. Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer CLOT Investigators  

ACC Current Journal Review, Vol. 12, Iss. 5, 2003-09 ,pp. : 19-20

Elsevier

Access to resources Recommend Favorite

For the Initial Treatment of Venous Thromboembolism - Are All Low-molecular-weight Heparin Compounds the Same?

By van der Heijden J.F.   Prins M.H.   Buller H.R.  

Thrombosis Research, Vol. 100, Iss. 2, 2000-10 ,pp. : 121-130

Elsevier

Access to resources Recommend Favorite

ENOXAPARIN, A LOW-MOLECULAR-WEIGHT HEPARIN SUPPRESSES PROTHROMBIN ACTIVATION MORE EFFECTIVELY THAN UNFRACTIONATED HEPARIN IN PATIENTS TREATED FOR VENOUS THROMBOEMBOLISM

By Grosset A.B.   Spiro T.E.   Beynon J.   Rodgers G.M.  

Thrombosis Research, Vol. 86, Iss. 5, 1997-06 ,pp. : 349-354

Elsevier

Access to resources Recommend Favorite

An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial

By the PROTEKT Study Group   Massicotte P.   Julian J.A.   Gent M.   Shields K.   Marzinotto V.   Szechtman B.   Chan A.K.   Andrew M.  

Thrombosis Research, Vol. 109, Iss. 2, 2003-01 ,pp. : 101-108

Elsevier

Access to resources Recommend Favorite